Grifols: positive results in Alzheimer's disease
(CercleFinance.com) - Plasma exchange followed by infusion of Grifols' human albumin showed a significant reduction in the progression of moderate Alzheimer's disease, the Spanish group said on Monday.
Results from a study that was designed to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmapheresis with infusion of Grifols' Albutein, combined with intravenous immunoglobulin, demonstrated a 61% reduction in disease's progression, the company said.
The study included 496 mild and moderate Alzheimer patients aged 55-85 years from 41 centres, randomised in three treatment groups and one control (placebo) group.
The Grifols stock was up 8.3% in Madrid on this news.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Results from a study that was designed to evaluate the efficacy and safety of short-term plasma exchange followed by long-term plasmapheresis with infusion of Grifols' Albutein, combined with intravenous immunoglobulin, demonstrated a 61% reduction in disease's progression, the company said.
The study included 496 mild and moderate Alzheimer patients aged 55-85 years from 41 centres, randomised in three treatment groups and one control (placebo) group.
The Grifols stock was up 8.3% in Madrid on this news.
Copyright (c) 2018 CercleFinance.com. All rights reserved.